Roche

File:Hoffmann-La Roche logo.svg

Founded in 1896 by Fritz Hoffmann-La Roche, the company was known early on for producing various vitamin preparations and derivatives.{{Cite news |title=Switzerland's Biggest Family Fortune Has Prospered for 124 Years |url=https://www.bloomberg.com/news/features/2020-08-06/switzerland-s-biggest-family-fortune-has-prospered-for-124-years |access-date=2022-03-16 |newspaper=Bloomberg.com|date = 6 August 2020}} In 1934, it became the first company to mass-produce synthetic vitamin C, under the brand name Redoxon. During the Second World War, Roche collaborated with the Nazi regime in Germany and used forced labour in its German and Polish-based factories.{{Cite web|url=https://www.swissinfo.ch/eng/chemical-firms-exploited-nazi-links--probe-found/2218350|title=Chemical firms exploited Nazi links, probe found|date=30 August 2001|access-date=6 February 2022|archive-date=6 February 2022|archive-url=https://web.archive.org/web/20220206230020/https://www.swissinfo.ch/eng/chemical-firms-exploited-nazi-links--probe-found/2218350|url-status=live}} They also moved all their Jewish employees to the United States to save them from Nazi attention.[https://www.latimes.com/archives/la-xpm-2005-oct-01-me-sternbach1-story.html Leo Sternbach, 97; Invented Valium, Many Other Drugs by THOMAS H. MAUGH II OCT. 1, 2005 L.A. Times]

In 1957, Hoffmann-La Roche introduced the class of tranquilizers known as benzodiazepines (with Valium and Rohypnol being the best known members).{{Cite web |last=HannahBlake |date=2012-11-01 |title=A history of Roche |url=https://pharmaphorum.com/articles/a_history_of-_roche/ |access-date=2022-03-16 |website=pharmaphorum.com |language=en-GB |archive-date=25 April 2022 |archive-url=https://web.archive.org/web/20220425214644/https://pharmaphorum.com/articles/a_history_of-_roche/ |url-status=live }} It manufactures and sells several cancer drugs and is a leader in this field. In 1956, the first antidepressant, iproniazid, was accidentally created during an experiment while synthesizing isoniazid. Originally, it had been intended to create a more efficient drug at combatting tuberculosis. Iproniazid, however, was revealed to have its own benefits; some people felt it made them feel happier. It was withdrawn from the market in the early 1960s due to toxic side-effects.

In 1976, an accident at a chemical factory in Seveso, Italy, owned by a subsidiary of Roche, caused a large dioxin contamination. In 1982, the United States arm of the company acquired Biomedical Reference Laboratories for US$163.5 million. That company dated from the late 1960s, and was located in Burlington, North Carolina. That year Hoffmann-La Roche then merged it with all of its laboratories, and incorporated the merged company as Roche Biomedical Laboratories, Inc. in Burlington. By the early 1990s, Roche Biomedical became one of the largest clinical laboratory networks in the United States, with 20 major laboratories and US$600 million in sales.{{cite web|url=http://www.fundinguniverse.com/company-histories/Roche-Biomedical-Laboratories-Inc-Company-History.html|title=Roche Biomedical Laboratories, Inc|publisher=FundingUniverse.com|access-date=3 September 2007|archive-date=22 January 2012|archive-url=https://web.archive.org/web/20120122142025/http://www.fundinguniverse.com/company-histories/Roche-Biomedical-Laboratories-Inc-Company-History.html|url-status=live}}

Roche has also produced various HIV tests and antiretroviral drugs. It bought the patents for the polymerase chain reaction (PCR) technique in 1992. In 1995, the era of highly active anti-retroviral therapy (HAART) was initiated by the United States FDA's approval of Hoffman LaRoche's HIV protease inhibitor, saquinavir. Within 2 years of its approval (and that of ritonavir 4 months later) annual deaths from AIDS in the United States fell from over 50,000 to approximately 18,000.{{Cite web | title = HIV Surveillance --- United States, 1981—2008 | url = https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6021a2.htm | access-date = 8 November 2013 | archive-date = 9 November 2013 | archive-url = https://web.archive.org/web/20131109001606/http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6021a2.htm | url-status = live }} On 28 April 1995, Hoffmann-La Roche sold Roche Biomedical Laboratories, Inc. to National Health Laboratories Holdings Inc. (which then changed its name to Laboratory Corporation of America Holdings).[http://www.secinfo.com/ds2yr.a4.htm Laboratory Corp of America Holdings · 10-Q · For 3/31/95] {{Webarchive|url=https://web.archive.org/web/20200921171040/http://www.secinfo.com/ds2yr.a4.htm |date=21 September 2020 }}, SECInfo.com, Filed On 5/15/95, SEC File 1-11353, Accession Number 920148-95-11 Roche acquired Syntex in 1994, and Chugai Pharmaceuticals in 2002.

Oseltamivir an antiviral drug used to combat influenza. Roche is the only drug company authorized to manufacture the drug, which was discovered by Gilead Sciences. Roche purchased the rights to the drug in 1996, and in 2005, settled a royalty dispute, agreeing to pay Gilead tiered royalties of 14–22% of annual net sales without adjusting the payments for manufacturing costs, as had been allowed in the original licensing agreement.{{cite news|url=http://www.redherring.com/Article.aspx?a=14507&hed=Roche%2C+Gilead+End+Tamiflu+Feud|work=Red Herring|title=Roche, Gilead End Tamiflu Feud|date=16 November 2005|access-date=5 April 2006|archive-date=1 August 2020|archive-url=https://web.archive.org/web/20200801164819/http://www.redherring.com/Article.aspx?a=14507&hed=Roche,+Gilead+End+Tamiflu+Feud|url-status=live}}

On 20 October 2005, Hoffmann-La Roche decided to license other companies to manufacture Oseltamivir.{{cite magazine|url=http://www.time.com/time/business/article/0,8599,1120533,00.html|archive-url=https://web.archive.org/web/20051022133611/http://www.time.com/time/business/article/0,8599,1120533,00.html|url-status=dead|archive-date=22 October 2005|title=Why Roche Released Tamiflu|access-date=2008-05-22|last=Kher|first=Unmesh|date=2005-10-19|magazine=Time}}

Also in 2005, Roche acquired the Swiss company GlycArt Biotechnology in order to acquire technology to afucosylate antibodies; one of its products in development was obinutuzumab, which gained FDA approval in November 2013 for the treatment of chronic lymphocytic leukemia.{{cite web |url=http://www.roche.com/media/store/releases/med-cor-2005-07-19.htm |archive-url=https://web.archive.org/web/20150205033013/http://www.roche.com/media/store/releases/med-cor-2005-07-19.htm |url-status=dead |archive-date=5 February 2015 |title=Roche - Roche acquires Swiss based GlycArt Biotechnology to strengthen expertise in therapeutic antibody research |publisher=roche.com |access-date=2015-04-29 |df=dmy-all }}[https://web.archive.org/web/20160305002757/https://ec.europa.eu/research/health/pdf/event04/joel-jean-mairet-31032011_en.pdf Presentation: GlycArt Biotechnology AG From Inception to trade sale – and what happened after...] by Dr. Joël Jean-Mairet. Brussels, March 31, 2011{{cite journal | last1 = Cameron | first1 = F | last2 = McCormack | first2 = PL | date = Jan 2014 | title = Obinutuzumab: first global approval | journal = Drugs | volume = 74 | issue = 1| pages = 147–54 | pmid = 24338113 | doi = 10.1007/s40265-013-0167-3 | s2cid = 40983655 }}

On 22 January 2008, Roche acquired Ventana Medical Systems for $3.4 billion.{{cite web|title=Roche buys Ventana|url=http://www.roche.com/media/media_releases/med-cor-2008-01-22.htm|access-date=2 June 2014|url-status=dead|archive-url=https://web.archive.org/web/20140605051428/http://www.roche.com/media/media_releases/med-cor-2008-01-22.htm|archive-date=5 June 2014|df=dmy-all}} On 2 January 2009, Roche acquired Memory Pharmaceuticals Corp.{{cite news|title=Roche buys Memory Pharmaceuticals|url=https://www.nytimes.com/2009/03/13/business/worldbusiness/13drugs.html|access-date=2 June 2014|work=The New York Times|first=Andrew|last=Pollack|date=12 March 2009|archive-date=6 August 2015|archive-url=https://web.archive.org/web/20150806194558/http://www.nytimes.com/2009/03/13/business/worldbusiness/13drugs.html|url-status=live}}

On 26 March 2009, Roche acquired Genentech for $46.8 billion.{{cite news|title=Roche buys Genentech|url=https://www.nytimes.com/2009/03/13/business/worldbusiness/13drugs.html|access-date=2 June 2014|work=The New York Times|first=Andrew|last=Pollack|date=12 March 2009|archive-date=6 August 2015|archive-url=https://web.archive.org/web/20150806194558/http://www.nytimes.com/2009/03/13/business/worldbusiness/13drugs.html|url-status=live}} On 12 March 2009, Roche agreed to fully acquire Genentech, in which it had held a majority stake since 1990,{{cite news |url=https://www.nytimes.com/1990/02/05/business/genentech-roche-deal-may-spur-similar-ties.html |title=Genentech-Roche Deal May Spur Similar Ties |last=Pollack |first=Andrew |work=The New York Times |date=5 February 1990 |access-date=2009-04-11 |archive-date=4 September 2020 |archive-url=https://web.archive.org/web/20200904013822/https://www.nytimes.com/1990/02/05/business/genentech-roche-deal-may-spur-similar-ties.html |url-status=live }} after eight months of negotiations. As a result of the Genentech acquisition, Roche moved its Palo Alto–based research facilities to their campus that straddles the border between Clifton, New Jersey and Nutley, New Jersey while Roche's United States headquarters, located on the New Jersey site since 1929, was moved to Genentech's facility in South San Francisco.{{cite news |url=http://business.timesonline.co.uk/tol/business/industry_sectors/health/article5897691.ece |title=Roche swallows Genentech in third large drugs deal |last=Bawden |first=Tom |work=The Times |date=13 March 2009 |access-date=2009-04-11 | location=London|archive-url=https://web.archive.org/web/20110612124041/http://business.timesonline.co.uk/tol/business/industry_sectors/health/article5897691.ece|archive-date=2011-06-12 |url-status=dead}} Genentech became a wholly owned subsidiary group of Roche on 25 March 2009.{{cite news |url=https://www.reuters.com/article/mergersNews/idUSLQ73529820090326 |title=Roche completes Genentech buy |last=Jucca |first=Lisa |author2=Cage, Sam |work=Reuters |date=26 March 2009 |access-date=2009-04-11 |archive-date=13 February 2023 |archive-url=https://web.archive.org/web/20230213113852/https://www.reuters.com/article/mergersNews/idUSLQ73529820090326 |url-status=live }} Roche began vacating the NJ site in 2012, and sold it off in 2016.{{cite news |url=https://www.northjersey.com/story/news/essex/nutley/2017/06/15/ex-roche-campus-reinvented-on-3-science-center/393841001/ |title=Ex-Roche campus reinvented as 'On3' science center |last=Proctor |first=Owen |work=northjersey.com |date=17 June 2017 |access-date=2022-08-30}}

Roche acquired Medingo Ltd. in April 2010, for $160 million{{cite web|title=Roche buys Medingo|url=http://www.roche.com/investors/ir_update/inv-update-2010-04-13.htm|access-date=2 June 2014|url-status=dead|archive-url=https://web.archive.org/web/20140112213107/http://www.roche.com/investors/ir_update/inv-update-2010-04-13.htm|archive-date=12 January 2014|df=dmy-all}} and BioImagene, Inc. in August for $100 million.{{cite web|title=Roche buysBioImagene|url=http://www.roche.com/investors/ir_update/inv-update-2010-08-23.htm|access-date=2 June 2014|url-status=dead|archive-url=https://web.archive.org/web/20140605051034/http://www.roche.com/investors/ir_update/inv-update-2010-08-23.htm|archive-date=5 June 2014|df=dmy-all}}

In 2011, the company received the International Society for Pharmaceutical Engineering Facility of the Year Award for Process Innovation for Roche's "MyDose" Clinical Supply project.{{cite web |url=http://www.facilityoftheyear.org/foyawinners2011 |title=2011 Facility of the Year Category winners |access-date=2012-06-28 |archive-date=29 April 2014 |archive-url=https://web.archive.org/web/20140429165758/http://www.facilityoftheyear.org/foyawinners2011 |url-status=live }} In March 2011, Roche acquired PVT Probenverteiltechnik GmbH for up to €85 million.{{cite web|title=Roche buys PVT|url=http://www.roche.com/investors/ir_update/inv-update-2011-03-15.htm|access-date=2 June 2014|url-status=dead|archive-url=https://web.archive.org/web/20140605051430/http://www.roche.com/investors/ir_update/inv-update-2011-03-15.htm|archive-date=5 June 2014|df=dmy-all}} In July 2010, Roche acquired mtm laboratories AG for up to 190 million EUR.{{cite web|title=Roche buys mtm labs|url=http://www.roche.com/investors/ir_update/inv-update-2011-07-19.htm|access-date=2 June 2014|url-status=dead|archive-url=https://web.archive.org/web/20140605051033/http://www.roche.com/investors/ir_update/inv-update-2011-07-19.htm|archive-date=5 June 2014|df=dmy-all}} In October, Roche acquired Anadys Pharmaceuticals, Inc. for $230 million.{{cite web|title=Roche buys Anadys|url=http://www.roche.com/investors/ir_update/inv-update-2011-10-17.htm|access-date=2 June 2014|url-status=dead|archive-url=https://web.archive.org/web/20140605051030/http://www.roche.com/investors/ir_update/inv-update-2011-10-17.htm|archive-date=5 June 2014|df=dmy-all}} In December, Roche announced it would acquire Munich-based Verum Diagnostica GmbH, gaining entry to the fastest-growing field in the coagulation diagnostics market.{{cite web|url=https://www.biospace.com/article/roche-acquires-b-verum-diagnostica-gmbh-b-for-11-million-/|title=Roche Acquires Verum Diagnostica GmbH for €11 Million|website=BioSpace|access-date=25 February 2019|archive-date=13 February 2023|archive-url=https://web.archive.org/web/20230213114156/https://www.biospace.com/article/roche-acquires-b-verum-diagnostica-gmbh-b-for-11-million-/|url-status=dead}}

On 26 June 2012, Roche announced the closure of the Nutley/Clifton campus, which was completed in 2013. The property is in the process of remediation.{{cite web|title=Roche announces closure of Nutley, NJ site|url=http://www.rocheusa.com/portal/usa/press_releases_nutley?siteUuid=re7180004&paf_gear_id=38400020&pageId=re7425113&synergyaction=show&paf_dm=full&nodeId=1414-483eca26c04011e1bf151d03aefa681a|access-date=28 June 2012|url-status=dead|archive-url=https://web.archive.org/web/20130518034353/http://www.rocheusa.com/portal/usa/press_releases_nutley?siteUuid=re7180004&paf_gear_id=38400020&pageId=re7425113&synergyaction=show&paf_dm=full&nodeId=1414-483eca26c04011e1bf151d03aefa681a|archive-date=18 May 2013|df=dmy-all}}

In July 2013, Roche Diagnostics acquired blood diagnostics company Constitution Medical Inc. for $220 million.{{cite web|title=Roche buys Constitution Medical|url=http://www.roche.com/investors/ir_update/inv-update-2013-07-02.htm|access-date=2 June 2014|url-status=dead|archive-url=https://web.archive.org/web/20140602200439/http://www.roche.com/investors/ir_update/inv-update-2013-07-02.htm|archive-date=2 June 2014|df=dmy-all}} Later, in September, Genentech announced it would acquire Arrayit Corporation.{{cite web|url=https://www.biospace.com/article/genentech-purchases-arrayit-corporation-technology-/|title=Genentech Purchases Arrayit Corporation Technology|website=BioSpace|access-date=25 February 2019|archive-date=13 February 2023|archive-url=https://web.archive.org/web/20230213114640/https://www.biospace.com/article/genentech-purchases-arrayit-corporation-technology-/|url-status=dead}}

On 7 April 2014, Roche announced its intention to acquire IQuum for up to $450 million,{{cite web|title=Roche buys IQuum|url=http://www.roche.com/investors/ir_update/inv-update-2014-04-07.htm|access-date=2 June 2014|url-status=dead|archive-url=https://web.archive.org/web/20140602195751/http://www.roche.com/investors/ir_update/inv-update-2014-04-07.htm|archive-date=2 June 2014|df=dmy-all}} as well as the rights to an experimental drug (ORY-1001) from Spanish company Oryzon Genomics for $21 million and up to $500 million in milestone payments.{{cite news|title=Roche buys experimental drug rights from Oryson |url=https://www.reuters.com/article/us-roche-oryzon-idUSBREA360KN20140407|access-date=2 June 2014 | work=Reuters|first=Caroline|last=Copley|date=7 April 2014}} On 2 June, Roche announced its intention to acquire Genia Technologies Inc. for up to $350 million.{{cite news|title=Roche buys Genia|url=https://www.bloomberg.com/news/2014-06-02/roche-agrees-to-buy-genia-technologies-for-up-to-350-million.html|access-date=2 June 2014|work=Bloomberg|first=Thomas|last=Mulier|date=2 June 2014|archive-date=31 October 2014|archive-url=https://web.archive.org/web/20141031130457/http://www.bloomberg.com/news/2014-06-02/roche-agrees-to-buy-genia-technologies-for-up-to-350-million.html|url-status=live}} In August 2014, the company agreed to purchase Californian-based pharmaceutical firm InterMune for $8.3 billion, at $74 a share this represents a 38% premium over the final share closing price,{{cite news|url=https://www.bloomberg.com/news/2014-08-24/roche-holding-agrees-to-buy-intermune-for-8-3-billion.html|title=Roche Holding Agrees to Buy InterMune for $8.3 Billion|author=Michelle Cortez|date=24 August 2014|publisher=Bloomberg L.P.|access-date=7 March 2017|archive-date=23 January 2015|archive-url=https://web.archive.org/web/20150123044641/http://www.bloomberg.com/news/2014-08-24/roche-holding-agrees-to-buy-intermune-for-8-3-billion.html|url-status=live}}{{cite news|title=Roche pays 37% premium on shares for InterMune in US $8.3bn deal|url=http://www.sanfrancisconews.net/index.php/sid/225058355/scat/3a8a80d6f705f8cc|date=24 August 2014|access-date=24 August 2014|publisher=San Francisco News.Net|archive-date=26 August 2014|archive-url=https://web.archive.org/web/20140826114357/http://www.sanfrancisconews.net/index.php/sid/225058355/scat/3a8a80d6f705f8cc|url-status=live}} as well as Santaris Pharma A/S for $450 million.{{cite web|url=https://www.biospace.com/article/roche-bags-santaris-pharma-a-s-in-deal-worth-450-million-/|title=Roche Bags Santaris Pharma A/S In Deal Worth $450 Million|website=BioSpace|access-date=25 February 2019|archive-date=22 September 2022|archive-url=https://web.archive.org/web/20220922144424/https://www.biospace.com/article/roche-bags-santaris-pharma-a-s-in-deal-worth-450-million-/|url-status=dead}} In December 2014, the company acquired next-generation sequencing processing company Bina Technologies for an undisclosed sum{{cite web|url=http://www.genengnews.com/gen-news-highlights/roche-acquires-big-data-platform-provider/81250725/|title=Roche Acquires Big Data Platform Provider|work=GEN|date=19 December 2014|access-date=20 December 2014|archive-date=25 December 2014|archive-url=https://web.archive.org/web/20141225033804/http://www.genengnews.com/gen-news-highlights/roche-acquires-big-data-platform-provider/81250725|url-status=live}} and Dutalys GmbH{{cite web|url=https://www.biospace.com/article/roche-to-pay-up-to-489-million-for-next-gen-antibody-firm-b-dutalys-b-/|title=Roche To Pay Up To $489 Million For Next-Gen Antibody Firm Dutalys|website=BioSpace|date=19 December 2014|access-date=28 November 2018|archive-date=26 February 2019|archive-url=https://web.archive.org/web/20190226172742/https://www.biospace.com/article/roche-to-pay-up-to-489-million-for-next-gen-antibody-firm-b-dutalys-b-/|url-status=live}} a developer of next-generation anti-bodies.

On 16 January 2015, the company announced that they would acquire Trophos for €470 million ($543 million) in order to increase the company's neuromuscular disease presence. The deal will centre on the Phase II and III spinal muscular atrophy drug olesoxime (TRO19622).{{cite web|url=http://www.genengnews.com/gen-news-highlights/roche-to-buy-trophos-for-up-to-543m/81250813/|title=Roche to Buy Trophos for Up-to-$543M|work=GEN|date=16 January 2015|access-date=16 January 2015|archive-date=18 January 2015|archive-url=https://web.archive.org/web/20150118194705/http://www.genengnews.com/gen-news-highlights/roche-to-buy-trophos-for-up-to-543m/81250813/|url-status=live}} In April 2015, Roche acquired CAPP Medical, and its chief development of technology for cancer screening and monitoring via the detection of circulating tumour DNA.{{cite web|url=https://www.biospace.com/article/roche-grabs-b-capp-medical-b-a-liquid-biopsy-startup-targeting-cancer-/|title=Roche Grabs CAPP Medical, a "Liquid Biopsy" Startup Targeting Cancer|website=BioSpace|access-date=25 February 2019|archive-date=26 February 2019|archive-url=https://web.archive.org/web/20190226172758/https://www.biospace.com/article/roche-grabs-b-capp-medical-b-a-liquid-biopsy-startup-targeting-cancer-/|url-status=live}}

In August, the company announced its intention to acquire GeneWEAVE, Inc. for up to $425 million in order to strengthen its microbial diagnostics business.{{cite web|url=http://www.genengnews.com/gen-news-highlights/roche-to-acquire-geneweave-for-up-to-425m/81251623/|title=Roche to Acquire GeneWEAVE for Up-to $425M|work=GEN|date=13 August 2015|access-date=14 August 2015|archive-date=15 August 2015|archive-url=https://web.archive.org/web/20150815023625/http://www.genengnews.com/gen-news-highlights/roche-to-acquire-geneweave-for-up-to-425m/81251623/|url-status=live}} Days later the company acquired Kapa Biosystems, Inc. for $445M, focussing on next generation sequencing and polymerase chain reaction applications.{{cite web|url=http://www.genengnews.com/gen-news-highlights/roche-acquires-genomic-tools-provider-kapa-biosystems/81251641/|title=Roche Acquires Genomic Tools Provider Kapa Biosystems|work=GEN|date=19 August 2015|access-date=19 August 2015|archive-date=21 August 2015|archive-url=https://web.archive.org/web/20150821003729/http://www.genengnews.com/gen-news-highlights/roche-acquires-genomic-tools-provider-kapa-biosystems/81251641/|url-status=live}} In October 2015, the company acquired Adheron Therapeutics for $105 million (plus up to $475 million in milestone payments).{{cite web|url=http://www.genengnews.com/gen-news-highlights/roche-to-acquire-adheron-therapeutics-for-105-upfront/81251839/|title=Roche to Acquire Adheron Therapeutics for $105 Upfront - GEN Genetic Engineering & Biotechnology News - Biotech from Bench to Business - GEN|website=GEN|date=9 October 2015|access-date=23 May 2017|archive-date=19 March 2017|archive-url=https://web.archive.org/web/20170319184256/http://www.genengnews.com/gen-news-highlights/roche-to-acquire-adheron-therapeutics-for-105-upfront/81251839|url-status=live}}

In January 2016, the company announced it would acquire Tensha Therapeutics for $115 million upfront, with $420 million in contingent payments.{{cite web|url=http://www.genengnews.com/gen-news-highlights/roche-acquires-tensha-therapeutics-for-115m-upfront/81252212/|title=Roche Acquires Tensha Therapeutics for $115M Upfront - GEN Genetic Engineering & Biotechnology News - Biotech from Bench to Business - GEN|website=GEN|access-date=23 May 2017|date=11 January 2016|archive-date=5 November 2016|archive-url=https://web.archive.org/web/20161105103607/http://www.genengnews.com/gen-news-highlights/roche-acquires-tensha-therapeutics-for-115m-upfront/81252212|url-status=live}}

In January 2017, the company acquired ForSight VISION4.{{cite press release|url=http://www.prnewswire.com/news-releases/forsight-vision4-inc-announces-acquisition-by-roche-300388249.html|title=ForSight VISION4, Inc. Announces Acquisition by Roche|first=ForSight VISION4|last=Inc.|agency=PR Newswire}} In June, the company acquired the diabetes management platform, mySugr GmbH for an undisclosed price.{{cite news|url=https://uk.reuters.com/article/us-roche-diabetes-acquisition-idUKKBN19L0H9|archive-url=https://web.archive.org/web/20170630060457/http://uk.reuters.com/article/us-roche-diabetes-acquisition-idUKKBN19L0H9|url-status=dead|archive-date=30 June 2017|title=Roche buys diabetes app firm in digital health push|first=John|last=Miller|work=Reuters|date=30 June 2017}} In November Roche acquired Viewics, Inc.{{cite web|url=https://www.biospace.com/article/roche-scoops-up-bay-area-s-viewics-amid-diagnostic-data-push/|title=Roche Scoops Up Bay Area's Viewics Amid Diagnostic Data Push|website=BioSpace|access-date=25 February 2019|archive-date=22 September 2022|archive-url=https://web.archive.org/web/20220922144429/https://www.biospace.com/article/roche-scoops-up-bay-area-s-viewics-amid-diagnostic-data-push/|url-status=dead}} In late December the company announced it would acquire Ignyta Inc, expanding its global oncology business.{{cite news|url=https://uk.reuters.com/article/us-ignyta-m-a-roche-idUKKBN1EG0HH|archive-url=https://web.archive.org/web/20181206213504/https://uk.reuters.com/article/us-ignyta-m-a-roche-idUKKBN1EG0HH|url-status=dead|archive-date=6 December 2018|title=Roche to buy U.S. cancer drugmaker Ignyta for $1.7 billion|date=22 December 2017|work=Reuters.com|agency=Reuters}}

In February 2018, Roche announced it would acquire Flatiron Health, a business specialising in US cancer data analytics, for $1.9 billion.{{cite news|url=https://www.ft.com/content/f79d2cc0-1290-11e8-940e-08320fc2a277 |archive-url=https://ghostarchive.org/archive/20221210/https://www.ft.com/content/f79d2cc0-1290-11e8-940e-08320fc2a277 |archive-date=10 December 2022 |url-access=subscription|title=Roche pays $1.9bn for Alphabet-backed Flatiron Health|website=Financial Times|date=15 February 2018|last1=Dye|first1=Jessica}}{{cite news|url=https://uk.reuters.com/article/uk-flatiron-health-m-a-roche-hldg-idUKKCN1FZ2R2|archive-url=https://web.archive.org/web/20181209073244/https://uk.reuters.com/article/uk-flatiron-health-m-a-roche-hldg-idUKKCN1FZ2R2|url-status=dead|archive-date=9 December 2018|title=Roche to buy Flatiron Health for $1.9 billion to expand cancer care...|date=15 February 2018|work=Reuters.com|agency=Reuters}} In June of the same year the company announced it would acquire the outstanding shares of Foundation Medicine for $2.4 billion ($137 per share).{{cite news|url=https://uk.reuters.com/article/us-roche-hldg-m-a-fmi-idUKKBN1JF0F3|archive-url=https://web.archive.org/web/20181209112650/https://uk.reuters.com/article/us-roche-hldg-m-a-fmi-idUKKBN1JF0F3|url-status=dead|archive-date=9 December 2018|title=Roche pays $2.4 billion for rest of cancer expert Foundation Medicine|date=19 June 2018|work=Reuters.com|agency=Reuters}} Later in September Roche announced its intention to acquire Tusk Therapeutics for up to €655 million ($759 million) expanding Roche's oncology pipeline. Tusk announced that the anti-CD38 antibody it is developing will be spun off to form a new company, Black Belt Therapeutics.{{cite web|url=https://www.genengnews.com/news/roche-acquires-cancer-immunotherapy-developer-tusk-therapeutics/|title=Roche Acquires Cancer Immunotherapy Developer Tusk Therapeutics|date=28 September 2018|access-date=25 February 2019|archive-date=26 February 2019|archive-url=https://web.archive.org/web/20190226111127/https://www.genengnews.com/news/roche-acquires-cancer-immunotherapy-developer-tusk-therapeutics/|url-status=live}} In late November, the company announced that Genentech would acquire Jecure Therapeutics, gaining access to Jecure's portfolio of NLRP3 inhibitors developed to fight inflammatory diseases like non-alcoholic steatohepatitis and liver fibrosis.{{cite news|url=https://uk.reuters.com/article/us-jecure-m-a-roche-hldg-idUKKCN1NW23L|archive-url=https://web.archive.org/web/20181128022526/https://uk.reuters.com/article/us-jecure-m-a-roche-hldg-idUKKCN1NW23L|url-status=dead|archive-date=28 November 2018|title=Roche buys U.S. biotech Jecure in race for liver disease drugs|date=27 November 2018|work=Reuters.com|agency=Reuters}}

In February 2019, the business announced it would acquire gene therapy company, Spark Therapeutics, for {{US$|4.3 billion}} ($114.50 per share) adding Spark's gene therapy portfolio to its previous acquired assets. Spark has an already approved treatment for Leber's congenital amaurosis, Luxturna – priced at {{US$|850,000}} per patient.{{cite news|url=https://uk.reuters.com/article/us-spark-m-a-roche-hldg-idUKKCN1QE0L6|archive-url=https://web.archive.org/web/20190225165145/https://uk.reuters.com/article/us-spark-m-a-roche-hldg-idUKKCN1QE0L6|url-status=dead|archive-date=25 February 2019|title=Roche 'steps up' for gene therapy with $4.3 billion Spark bet|date=25 February 2019|work=Reuters.com|agency=Reuters}} The offer to acquire Spark Therapeutics was extended to May 2019 after Roche was unable to garner majority support from Spark shareholders.{{cite web |title=Roche says its $4.3 billion offer for Spark is still on track for June completion |url=https://www.cnbc.com/2019/04/03/roche-says-its-4point3-billion-offer-for-spark-is-still-on-track-for-june-completion.html |publisher=CNBC |date=3 April 2019 |access-date=10 April 2019 |archive-date=10 April 2019 |archive-url=https://web.archive.org/web/20190410111422/https://www.cnbc.com/2019/04/03/roche-says-its-4point3-billion-offer-for-spark-is-still-on-track-for-june-completion.html |url-status=live }} A second gene therapy-related action came in December with the {{US$|1.15 billion}} acquisition of non-United States rights to an investigational duchenne muscular dystrophy gene therapy developed by Sarepta Therapeutics.{{Cite news|url=https://www.reuters.com/article/us-roche-sarepta/roche-dives-deeper-into-gene-therapy-with-1-15-billion-sarepta-licensing-deal-idUSKBN1YR0G6|title=Roche dives deeper into gene therapy with $1.15 billion Sarepta licensing deal|last1=Koltrowitz|first1=Silke|date=23 December 2019|access-date=24 December 2019|work=Reuters|last2=Nadeem|first2=Dania|archive-date=23 December 2019|archive-url=https://web.archive.org/web/20191223215340/https://www.reuters.com/article/us-roche-sarepta/roche-dives-deeper-into-gene-therapy-with-1-15-billion-sarepta-licensing-deal-idUSKBN1YR0G6|url-status=live}} In November, Roche acquired Promedior and its lead treatment – PRM-151 – for the treatment of idiopathic pulmonary fibrosis, for $390 million upfront and another $1 billion in milestone payments.{{Cite web | url=https://www.biospace.com/article/roche-snaps-up-ipf-aimed-therapeutic-in-acquisition-of-promedior/?s=79 |title = Roche to Acquire Fibrosis-Focused Promedior for up to $1.4 Billion| date=15 November 2019 }}{{Cite web | url=https://www.biospace.com/article/releases/promedior-enters-into-definitive-merger-agreement-to-be-acquired-by-roche/ |title = Promedior Enters into Definitive Merger Agreement to be Acquired by Roche| date=15 November 2019 }}

In March 2020, the Roche Diagnostics division reached a significant milestone with the FDA-approval of its high-volume Sars-CoV-2 diagnostic test, capable of analysing 1,400-8,800 samples within 24h on the proprietary Cobas 6800/8800 molecular testing system.Hale C. (March 2020). [https://www.fiercebiotech.com/medtech/fda-grants-roche-coronavirus-test-emergency-green-light-within-24-hours "FDA grants Roche coronavirus test emergency green light within 24 hours"] {{Webarchive|url=https://web.archive.org/web/20200314145725/https://www.fiercebiotech.com/medtech/fda-grants-roche-coronavirus-test-emergency-green-light-within-24-hours |date=14 March 2020 }} FierceBiotech. Retrieved 13 March 2020. In September, the business acquired Ireland-based Inflazome, for €380 million, gaining control of its NLRP3 inflammasome inhibitors.{{Cite web|url=https://www.biospace.com/article/roche-dives-into-nlrp3-inflammasome-inhibition-with-acquisition-of-inflazome/|title=Roche Dives into NLRP3 Inflammasome Inhibition with Acquisition of Inflazome|website=BioSpace|date=21 September 2020|access-date=22 September 2020|archive-date=8 October 2020|archive-url=https://web.archive.org/web/20201008051959/https://www.biospace.com/article/roche-dives-into-nlrp3-inflammasome-inhibition-with-acquisition-of-inflazome/|url-status=live}}{{Cite web|url=https://www.biospace.com/article/inflazome-announces-acquisition-by-roche/|title=Inflazome Announces Acquisition by Roche|website=BioSpace|access-date=3 January 2021|archive-date=22 September 2022|archive-url=https://web.archive.org/web/20220922144422/https://www.biospace.com/article/inflazome-announces-acquisition-by-roche/|url-status=dead}}

In March 2021, Roche announced it would acquire GenMark Diagnostics for $1.8 billion.{{Cite web|url=https://www.biospace.com/article/roche-acquires-genmark-diagnostics-and-its-covid-19-test-in-1-8-billion-deal/?s=79|title=Roche Bolsters Diagnostics Pipeline with $1.8 Billion Buy of GenMark|date=15 March 2021|access-date=15 March 2021|archive-date=25 April 2022|archive-url=https://web.archive.org/web/20220425212549/https://www.biospace.com/article/roche-acquires-genmark-diagnostics-and-its-covid-19-test-in-1-8-billion-deal/?s=79|url-status=live}}{{cite news |title=Roche buys GenMark for $1.8 million to challenge test rivals |website=Reuters |date=15 March 2021 |archive-url=https://web.archive.org/web/20230213115919/https://www.reuters.com/article/us-roche-genmark/roche-buys-genmark-for-1-8-million-to-challenge-test-rivals-idUSKBN2B70JH |archive-date=2023-02-13 |url-status=live |url=https://www.reuters.com/article/us-roche-genmark/roche-buys-genmark-for-1-8-million-to-challenge-test-rivals-idUSKBN2B70JH}} Under the terms of agreement, Genmark diagnostics will become a subsidiary and the principal operations will continue to remain in Carlsbad, California.{{Cite web|url=https://www.roche.com/media/releases/med-cor-2021-03-15b.htm|title=Roche signs definitive merger agreement with GenMark Diagnostics, Inc., to access novel technology to test for broad range of pathogens with one patient sample|access-date=2 May 2021|archive-date=28 April 2021|archive-url=https://web.archive.org/web/20210428095008/https://www.roche.com/media/releases/med-cor-2021-03-15b.htm|url-status=live}} In September, the company announced it would acquire German biotech group, TIB Molbiol, enhancing its molecular diagnostics operations.{{Cite news|url=https://www.reuters.com/article/tibmolbiol-m-a-roche-hldg/roche-holding-to-buy-tib-molbiol-to-enhance-molecular-diagnostics-idUSKBN2G50D1|title = Roche Holding to buy TIB Molbiol to enhance molecular diagnostics|work = Reuters|date = 9 September 2021}}

In September 2022, Roche acquired Good Therapeutics at a cost of $250M for its PD1-regulated IL-2 receptor agonist program.{{Cite web |date=2022-09-07 |title=Good Therapeutics Announces Acquisition of Conditionally Active PD-1-regulated IL-2 Program by Roche |url=https://www.businesswire.com/news/home/20220907005310/en/Good-Therapeutics-Announces-Acquisition-of-Conditionally-Active-PD-1-regulated-IL-2-Program-by-Roche |access-date=2023-07-17 |website=www.businesswire.com |language=en |archive-date=17 July 2023 |archive-url=https://web.archive.org/web/20230717132928/https://www.businesswire.com/news/home/20220907005310/en/Good-Therapeutics-Announces-Acquisition-of-Conditionally-Active-PD-1-regulated-IL-2-Program-by-Roche |url-status=live }}{{Cite web |last=Garde |first=Damian |date=2022-09-07 |title=Roche pays $250 million to acquire Good Therapeutics and its preclinical cancer therapy |url=https://www.statnews.com/2022/09/07/roche-pays-250-million-to-acquire-good-therapeutics-and-its-preclinical-cancer-therapy/ |access-date=2023-07-17 |website=STAT |language=en-US |archive-date=17 July 2023 |archive-url=https://web.archive.org/web/20230717133833/https://www.statnews.com/2022/09/07/roche-pays-250-million-to-acquire-good-therapeutics-and-its-preclinical-cancer-therapy/ |url-status=live }}

In July 2023, Roche partnered with Alnylam Pharmaceuticals in a deal worth $2.8 billion for the development of a hypertension drug.{{Cite news |date=2023-07-24 |title=Roche Signs $2.8 Billion Alnylam Deal for Hypertension Drug |language=en |work=Bloomberg.com |url=https://www.bloomberg.com/news/articles/2023-07-24/roche-signs-2-8-billion-alnylam-deal-for-hypertension-drug |access-date=2023-07-25}} In December 2023, Roche acquired Carmot Therapeutics, an anti-obesity drug developer, for $2.7 billion.{{Cite web |last= |first= |date=2023-12-04 |title=Roche enters obesity market with Carmot takeover but drugs may not be available until 2030 |url=https://www.cnbc.com/2023/12/04/roche-enters-obesity-market-with-carmot-takeover.html |access-date=2023-12-08 |website=CNBC |language=en}}

In October 2023, Monte Rosa Therapeutics and Roche signed a strategic cooperation and licensing agreement for the discovery and development of molecular adhesive degradators (MGD) to combat cancer and neurological diseases. The partnership includes Monte Rosa’s QuEENT discovery engine and Roche Holding expertise. Also Monte Rosa will receive $50m as an upfront payment and additional payments that will depend on the pre-clinical, clinical, commercial stages and sales, as well as multi-level royalty system and may exceed $2 billion.{{Cite web|language=en|url=https://www.pharmaceutical-technology.com/news/monte-rosa-roche-development-mgds/|title=Monte Rosa and Roche partner for development of MGDs|website=Pharmaceutical Technology|date=18 October 2023 |access-date=2024-02-27|archive-date=2023-10-28|archive-url=https://web.archive.org/web/20231028232656/https://www.pharmaceutical-technology.com/news/monte-rosa-roche-development-mgds/}}

In March 2024, it was announced Roche had sold Genentech's site in Vacaville, California to the Swiss pharmaceutical company, Lonza for $1.2 billion.{{Cite web |date=2024-03-20 |title=Lonza to acquire biologics site in Vacaville, US from Roche for $1.2bn - Pharmafile |url=https://pharmafile.com/news/lonza-to-acquire-biologics-site-in-vacaville-us-from-roche-for-1-2bn/ |access-date=2024-03-20 |website=pharmafile.com |language=en-GB}}

In November 2024, Roche acquired Poseida Therapeutics for US $1.0 billion.{{Cite web |title=Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies |url=https://www.roche.com/media/releases/med-cor-2024-11-26b |access-date=2024-11-26 |website=www.roche.com}}{{Cite web |last= |last2= |last3= |last4= |last5= |last6= |title=Roche to buy cell therapy developer Poseida for $1B |url=https://www.biopharmadive.com/news/roche-poseida-acquisition-deal-cell-therapy-cancer/734021/ |access-date=2024-11-26 |website=BioPharma Dive |language=en-US}}

In April 2025, Roche announced it would invest $50 billion in the United States over the next five years, creating more than 12,000 new jobs.{{Cite web |last=Smolak |first=Helena |title=Roche to Invest $50 Billion in U.S. Manufacturing, R&D as Tariffs Loom |url=https://www.wsj.com/health/pharma/roche-to-invest-50-billion-in-u-s-manufacturing-r-d-amid-tariff-threats-e3611e50 |access-date=2025-04-22 |website=WSJ |language=en-US}}

The Hoffmann-La Roche family is Switzerland's richest and one of the most secretive families.{{cite news | url=https://www.bloomberg.com/news/features/2020-08-06/switzerland-s-biggest-family-fortune-has-prospered-for-124-years | title=Switzerland's Biggest Family Fortune Has Prospered for 124 Years | newspaper=Bloomberg.com | date=6 August 2020 | access-date=15 April 2022 | archive-date=10 September 2021 | archive-url=https://web.archive.org/web/20210910170300/https://www.bloomberg.com/news/features/2020-08-06/switzerland-s-biggest-family-fortune-has-prospered-for-124-years | url-status=live }} Many members of the family don't carry the last name Hoffmann anymore. Some are known as Oeri, Michalski, Faber-Castell, Fabre, Schmid or Duschmalé.{{cite web | url=https://www.bzbasel.ch/basel/125-jahr-jubilaeum-nachkomme-und-verwaltungsrat-joerg-duschmale-roche-war-immer-da-seit-ich-ganz-klein-war-ld.2189054?reduced=true | title=Nachkomme und Verwaltungsrat Jörg Duschmalé: "Roche war immer da, seit ich ganz klein war" | date=18 September 2021 | access-date=9 July 2022 | archive-date=9 July 2022 | archive-url=https://web.archive.org/web/20220709121839/https://www.bzbasel.ch/basel/125-jahr-jubilaeum-nachkomme-und-verwaltungsrat-joerg-duschmale-roche-war-immer-da-seit-ich-ganz-klein-war-ld.2189054?reduced=true | url-status=live }}

{{hidden begin|border=1px #aaa solid|title=Roche acquisitions|ta1=center}}

{{Tree list}}

• Hoffmann-La Roche {{small|(Founded 1896 by Fritz Hoffmann-La Roche)}}
• Biomedical Reference Laboratories {{small|(Acq 1982, restructured into Roche Biomedical Laboratories, Inc in 1982, sold 1995)}}
• Syntex {{small|(Acq 1994)}}
• Chugai Pharmaceuticals {{small|(Acq 2002)}}
• 454 Life Sciences {{small|(Acq 2007)}}
• Roche Diagnostics
• Spring BioScience Corp {{small|(Acq 2007)}}
• Ventana Medical Systems {{small|(Acq 2009)}}
• mySugr GmbH {{small|(Acq 2017)}}
• Viewics, Inc {{small|(Acq 2017)}}
• Flatiron Health {{small|(Acq 2018)}}
• Stratos Genomics {{small|(Acq 2020)}}
• Memory Pharmaceuticals Corp {{small|(Acq 2009)}}
• Genentech {{small|(Acq 2009)}}
• Tanox, Inc {{small|(Acq 2006)}}
• Arrayit Corporation {{small|(Acq 2013)}}
• Seragon {{small|(Acq 2014)}}
• Jecure Therapeutics {{small|(Acq 2018)}}
• Medingo Ltd {{small|(Acq 2010)}}
• BioImagene, Inc. {{small|(Acq 2010)}}
• PVT Probenverteiltechnik GmbH {{small|(Acq 2010)}}
• MTM laboratories AG {{small|(Acq 2010)}}
• Anadys Pharmaceuticals, Inc. {{small|(Acq 2010)}}
• Verum Diagnostica GmbH {{small|(Acq 2011)}}
• Constitution Medical Inc. {{small|(Acq 2012)}}
• IQuum {{small|(Acq 2014)}}
• Genia Technologies Inc. {{small|(Acq 2014)}}
• InterMune {{small|(Acq 2014)}}
• Santaris Pharma A/S {{small|(Acq 2014)}}
• Bina Technologies, Inc. {{small|(Acq 2014)}}
• Dutalys GmbH {{small|(Acq 2014)}}
• Ariosa Diagnostics {{small|(Acq 2014)}}
• Trophos {{small|(Acq 2015)}}
• CAPP Medical {{small|(Acq 2015)}}
• GeneWEAVE BioSciences, Inc. {{small|(Acq 2015)}}
• Kapa Biosystems, Inc. {{small|(Acq 2015)}}
• Adheron Therapeutics {{small|(Acq 2015)}}
• Tensha Therapeutics {{small|(Acq 2016)}}
• ForSight VISION4 {{small|(Acq 2017)}}
• Ignyta Inc {{small|(Acq 2017)}}
• Foundation Medicine, Inc. {{small|(Acq 2018)}}
• Tusk Therapeutics {{small|(Acq 2018)}}
• Spark Therapeutics {{small|(Acq 2019)}}
• Promedior {{small|(Acq 2019)}}
• Stratos Genomics {{small|(Acq 2020)}}
• Inflazome {{small|(Acq 2020)}}
• GenMark Diagnostics {{small|(Acq 2021)}}
• TIB Molbiol {{small|(Acq 2021)}}
• Good Therapeutics {{small|(Acq 2022)}}{{cite web|url=https://www.businesswire.com/news/home/20220907005310/en/Good-Therapeutics-Announces-Acquisition-of-Conditionally-Active-PD-1-regulated-IL-2-Program-by-Roche |title=Good Therapeutics Announces Acquisition of Conditionally Active PD-1-regulated IL-2 Program by Roche |date=September 2022 |website=Businesswire |access-date=July 17, 2023}}
• Telavant {{small|(Acq 2023)}}{{Cite news |url=https://www.reuters.com/markets/deals/roche-buys-telavant-holdings-71-billion-2023-10-23/ |title=Roche buys U.S. rights to Roivant bowel disease drug in $7.1 billion deal |date=23 October 2023 |last1=Burger |first1=Ludwig |last2=Revill |first2=John |publisher=Reuters |access-date=13 March 2024 |archive-date=1 November 2023 |archive-url=https://web.archive.org/web/20231101101424/https://www.reuters.com/markets/deals/roche-buys-telavant-holdings-71-billion-2023-10-23/ |url-status=live }}
• Carmot Therapeutics {{small|(Acq 2023)}}

{{Tree list/end}}

{{hidden end}}

{{More citations needed section|date=April 2022}}

Roche has two major divisions: Pharmaceuticals and Diagnostics.

Roche Diagnostics manufactures diagnostic equipment and reagents for research and medical diagnostic applications. Internally, it is organised into five major business areas: Roche Applied Science, Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics and Roche Tissue Diagnostics (Ventana). The main location for Roche Professional Diagnostics is in Rotkreuz, Switzerland.{{cite web |url=https://assets.cwp.roche.com/f/126832/x/8df367bf68/fb21e.pdf |title=Financial Report 2021 |date=4 February 2022 |access-date=5 April 2022 |publisher=Roche Holding |archive-date=23 February 2022 |archive-url=https://web.archive.org/web/20220223130813/https://assets.cwp.roche.com/f/126832/x/8df367bf68/fb21e.pdf |url-status=live }}

All business areas except Roche Applied Science focus on health care applications, targeting either physicians, hospitals and clinics, or consumers. Applied Science targets research settings in academia and pharmaceutical and biotechnology industries.

{{more citations needed section|date=January 2020}}

Hoffmann-La Roche develops drugs used for cancer treatment, against virus diseases and for treatment of metabolic diseases. The company is the world's largest spender in pharmaceutical R&D.{{cite news|last1=Miller|first1=John|title=Roche touts Swiss-led R&D unit after years in Genentech's shadow|url=https://www.reuters.com/article/us-roche-swiss-research/roche-touts-swiss-led-rd-unit-after-years-in-genentechs-shadow-idUSKBN1ED0KA|access-date=19 December 2017|work=Reuters|date=19 December 2017|archive-date=19 December 2017|archive-url=https://web.archive.org/web/20171219092320/https://www.reuters.com/article/us-roche-swiss-research/roche-touts-swiss-led-rd-unit-after-years-in-genentechs-shadow-idUSKBN1ED0KA|url-status=live}}

File:Tamiflu.JPG

Drugs produced by Roche include:{{update after|2020|1|8}}{{Original research inline|date=January 2020}}{{citation needed|date=January 2020}}

• Accutane/RoAccutane (isotretinoin), for severe (nodular) acne vulgaris - no longer sold under Accutane brand name but is still available as RoAccutane, other brand names and Isotretinoin generics.{{Cite news|title = Roche stops selling acne drug Accutane|url = https://www.reuters.com/article/us-roche-acne-idUSTRE55P53C20090626|work = Reuters|date = 2009-06-26|access-date = 2016-02-23}}
• Actemra/RoActemra (tocilizumab), for rheumatoid arthritis.
• Actimmune (interferon gamma), for chronic granulomatous disease, later sold to Connetics Corporation, then InterMune, after that Vidara Therapeutics and finally Horizon Pharma as of 2019.
• Activase (alteplase), for heart attacks.
• Akynzeo (netupitant/palonosetron), for nausea and vomiting, licensed by Eisai Co. and Helsinn Therapeutics.
• Alecensa (alectinib), for ALK-positive non-small cell lung cancer.
• Aloxi (palonosetron), for nausea and vomiting, licensed by Eisai Co. and Helsinn Therapeutics.
• Anexate (flumazenil), for the reversal of acute benzodiazepine effects.
• Aurorix (moclobemide), for depression.
• Avastin (bevacizumab), for certain malignant tumours.
• Bactrim (trimethoprim/sulfamethoxazole), a sulphonamide antibacterial.
• Boniva Bonviva (ibandronic acid), for the treatment of osteoporosis in postmenopausal females.
• Camleed (enprostil), for gastric ulcer prevention.
• Cardene (nicardipine), for treatment of stable angina pectoris.
• Cathflo Activase (alteplase), for heart attacks.
• Cellcept (mycophenolate mofetil), for transplant rejection.
• Cotellic (cobimetinib), for melanoma.
• Cymevene (ganciclovir), for cytomegalovirus infection.
• Dalmane Dalmadorm (flurazepam), for insomnia.
• Dilatrend (carvedilol), for hypertension and congestive heart failure.
• Dormicum (midazolam), for insomnia and procedural sedation and analgesia.
• Erivedge (vismodegib), for basal-cell carcinoma.
• Esbriet (pirfenidone), for idiopathic pulmonary fibrosis.
• Fansidar (sulfadoxine/pyrimethamine), for malaria and toxoplasmosis.
• Fuzeon (enfuvirtide), for salvage therapy of HIV-1 infection.
• Gazyva (obinutuzumab), for chronic lymphocytic leukaemia.
• Hemlibra (emicizumab), for haemophilia A.
• Herceptin (trastuzumab), for HER-2 positive breast cancer.
• Hivid (zalcitabine), for HIV-1 infection, later discontinued in 2006.
• Inhibace (cilazapril), for hypertension and congestive heart failure.
• Invirase (saquinavir), for HIV-1 infection.
• Kadcyla (trastuzumab emtansine), for HER-2 positive breast cancer.
• Klonopin Rivotril (clonazepam), for epilepsy and anxiety disorders.
• Kytril (granisetron), for chemotherapy-induced nausea and vomiting, licensed by GlaxoSmithKline.
• Lariam (mefloquine), for malaria (both prevention and treatment).
• Lexotanil (bromazepam), for anxiety disorders.
• Librax (Chlordiazepoxide/clidinium bromide), treating stomach ulcers, irritable bowel syndrome, or symptoms related to intestinal infection.
• Librium (chlordiazepoxide), for anxiety disorders.
• Lucentis (ranibizumab), for wet age-related macular degeneration (AMD).
• Luxturna (voretigene neparvovec), for Leber's congenital amaurosis.
• MabThera (rituximab), for B-cell chronic lymphocytic leukaemia (and other haematological malignancies), non-Hodgkin lymphomas and rheumatoid arthritis.
• Madopar/Prolopa (levodopa [[benserazide), for Parkinson's disease.
• Mircera (methoxy polyethylene glycol-epoetin beta), for anaemia associated with chronic kidney disease.
• Naprosyn (naproxen), a NSAID used for pain relief and arthritis treatment.
• Neulastim (pegfilgrastim), for neutropaenia.
• Neupogen (filgrastim), for neutropaenia.
• Nutropin (somatropin), for growth hormone deficiency.
• Nutropin AQ (somatropin), for growth hormone deficiency.
• Nutropin Depot (somatropin), for growth hormone deficiency, later discontinued in 2004 and replaced by Nutropin AQ.
• Ocrevus (ocrelizumab), for MS.
• Peginterferon/alfa-2a|Pegasys]], (peginterferon alfa-2a) for hepatitis B and C.
• Perjeta (pertuzumab), for HER-2 positive breast cancer.
• Polatuzumab vedotin|Polivy (polatuzumab vedotin), for diffuse large B-cell lymphoma.
• Protropin (somatrem), for growth hormone deficiency, later discontinued in 2004 in favor of its successor, Nutropin.
• Pulmozyme (dornase alfa), for the improvement of pulmonary function in cystic fibrosis.
• Raptiva (efalizumab), for psoriasis, later withdrawn in 2009 due to the risk of PML.
• Recormon NeoRecormon (epoetin beta), for anaemia.
• Rituxan (rituximab), for non-Hodgkin's lymphoma.
• Rocaltrol (calcitriol), for osteoporosis and hypocalcaemia.
• Rocephin (ceftriaxone), a broad-spectrum cephalosporin antibiotic.
• Roferon A (peginterferon alfa-2a), for some haematological malignancies (hairy cell leukaemia, chronic myelogenous leukaemia), certain solid tumours (including Kaposi's sarcoma), genital warts and chronic hepatitis C.
• Rohypnol (flunitrazepam), for severe insomnia.
• Rozlytrek (entrectinib), for ROS1-positive non-small cell lung cancer and NTRK fusion-positive solid tumours.
• Soriatane/Neotigason (acitretin), for psoriasis.
• Tamiflu (oseltamivir), for influenza A and B (both treatment and prevention).
• Tarceva (erlotinib), for various cancers.
• Tasmar (tolcapone), for parkinson's disease, licensed by Mylan and Bausch Health.
• Tecentriq (atezolizumab), for non-small cell lung cancer.
• TNKase (tenecteplase), for heart attacks.
• Toradol (ketorolac), for pain management.
• Valcyte (valganciclovir), for cytomegalovirus infection.
• Valium (diazepam), for anxiety disorders, alcohol withdrawal, status epilepticus and other conditions.
• midazolam|Versed (midazolam), for insomnia and procedural sedation and analgesia.
• Vesanoid (tretinoin), for acute promyelocytic leukaemia.
• Viracept (nelfinavir), for HIV-1 infection, licensed by Pfizer and ViiV Healthcare.
• Xeloda (capecitabine), for breast and colorectal cancer.
• Xenical (orlistat), for obesity.
• Xofluza (baloxavir marboxil), for influenza A and B (both treatment and prevention).
• Xolair (omalizumab), for asthma, chronic idiopathic urticaria (CIU), and nasal polyps.{{Cite web |title=FDA approves Xolair® (omalizumab) for adults with nasal polyps |url=https://www.roche.com/media/releases/med-cor-2020-12-01 |access-date=2023-09-21 |website=www.roche.com |archive-date=7 October 2023 |archive-url=https://web.archive.org/web/20231007222830/https://www.roche.com/media/releases/med-cor-2020-12-01 |url-status=live }}
• Zelboraf (vemurafenib), for late-stage V600E BRAF mutation-positive melanoma.
• Zenapax (daclizumab), for the prevention of acute transplant rejection.

Diabetes management products under the Accu-Chek brand include blood glucose meter, test strips and insulin pumps, as well as diabetes management software.

Other products include:

• Cobas Mira

{{see also|Cartel}}

Stanley Adams, Roche's World Product Manager in Basel, contacted the European Economic Community in 1973 with evidence that Roche had been breaking antitrust laws, engaging in price fixing and market sharing for vitamins with its competitors. Roche was fined accordingly, but a bungle on the part of the EEC allowed the company to discover that it was Adams who had blown the whistle. He was arrested for unauthorised disclosure — an offence under Swiss law — and imprisoned. His wife, having learnt that he might face decades in jail, committed suicide.{{cite news | url=https://www.theguardian.com/business/2001/nov/25/businessofresearch.research | title=Blowing the final whistle | last = Mathiason | first = Nick| work=The Observer | date=25 November 2001 | access-date=30 September 2014}}

In 1999 the firm pleaded guilty to participation in a worldwide conspiracy to raise and fix prices for vitamins sold in the US and globally. Hoffmann-La Roche paid $500 million in criminal fines to the United States.[http://www.corporatecrimereporter.com/top100.html#Annotated Corporate Crime Reporter]. Corporate Crime Reporter. Retrieved 2013-11-24.{{cite journal|url=http://capcp.psu.edu/papers/cartelpriceannouncements.pdf|archive-url=https://web.archive.org/web/20160820081831/http://capcp.psu.edu/papers/cartelpriceannouncements.pdf|url-status=dead|archive-date=20 August 2016|title=Cartel price announcements: The vitamins industry|year=2008|journal=International Journal of Industrial Organization|volume=26}}

During the Second World War, Roche was reported to have collaborated with the Nazi regime in Germany and used prisoners-of-war or foreign forced labour in its German and Polish-based factories.

In 2008 the Association of the British Pharmaceutical Industry (ABPI) suspended Roche for six months for breaching their code of conduct.{{Cite web |title=Roche is suspended from ABPI for "actions likely to bring discredit" on the industry |url=https://www.bmj.com/content/bmj/337/7662/News.full.pdf |website=BJM}}

In 2013, Roche had to pay back {{CHF|3.2|link=yes}}{{nbsp}}billion to the Swiss tax authorities due to transfer mispricing.{{cn|date=July 2024}}

In addition to internal research and development activities F. Hoffmann-La Roche is also involved in publicly funded collaborative research projects, with other industrial and academic partners. One example in the area of non-clinical safety assessment is the InnoMed PredTox.{{Cite book| last1 = Mattes | first1 = William B.| chapter = Public Consortium Efforts in Toxicogenomics | doi = 10.1007/978-1-60327-048-9_11 | title = Essential Concepts in Toxicogenomics| editor1-last = Mendrick | editor1-first = Donna L.| editor2-last = Mattes | editor2-first = William B.| series = Methods in Molecular Biology| volume = 460 | pages = 221–238 | year = 2008 | isbn = 978-1-58829-638-2 | pmid = 18449490 }}{{cite web|url=http://www.innomed-predtox.com/consortium/members/ |title=InnoMed PredTox Member Organizations |access-date=2008-08-25 |url-status=dead |archive-url=https://web.archive.org/web/20080926214522/http://www.innomed-predtox.com/consortium/members/ |archive-date=26 September 2008 |df=dmy }} The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of EFPIA and the European Commission.{{cite web|url=http://imi.europa.eu/docs/calls01_en.zip|title=IMI Call Topics 2008|last=Innovative Medicines Initiative|work=IMI-GB-018v2-24042008-CallTopics.pdf|publisher=European Commission|access-date=2008-08-25|archive-url=https://web.archive.org/web/20091015122459/http://imi.europa.eu/docs/calls01_en.zip|archive-date=15 October 2009|url-status=dead|df=dmy-all}}

• List of pharmaceutical companies
• Pharmaceutical industry in Switzerland

{{Reflist|30em}}

• Hans Conrad Peyer (1996) Roche – A Company History 1896–1996 Basel: Editiones Roche {{ISBN|3-907770-59-5}}

{{Commons category}}

• {{Official website|www.roche.com}}
• {{OpenSecrets}}

{{Pharmaceutical companies of Switzerland}}

{{Swiss Market Index companies}}

{{Swiss Leader Index companies}}

{{SMI MID companies}}

{{DJSI World}}

{{Portal bar|Companies|Switzerland}}

{{authority control}}

Category:Multinational companies headquartered in Switzerland

Category:Price fixing convictions

Category:Pharmaceutical companies of Switzerland

Category:Pharmaceutical companies established in 1896

Category:Life sciences industry

Category:Swiss brands

Category:Companies listed on the SIX Swiss Exchange

Category:Companies in the Swiss Market Index

Category:Companies in the Dow Jones Global Titans 50